Details of the Drug

General Information of Drug (ID: DM0FXMZ)

Drug Name

APG-101

Synonyms

CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix

Indication

Disease Entry	ICD 11	Status	REF
Cerebrovascular ischaemia	8B1Z	Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D0N4JI

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis mediating surface antigen FAS (FAS)	TTF0RCZ	TNR6_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Cerebrovascular ischaemia

ICD Disease Classification

8B1Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Apoptosis mediating surface antigen FAS (FAS)	DTT	FAS	1.08E-03	-0.69	-2.65

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01071837) APG101 in Glioblastoma. U.S. National Institutes of Health.
2	Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.